NGNE

SEC source: 0001606302-26-000007 · wk-form4_1790966949.xml · derivative · entry 2

McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 756 shares

Expires 2026-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option is fully vested and exercisable.

SEC source: 0001606302-26-000007 · wk-form4_1790966949.xml · nonDerivative · entry 1

McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,345,063

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.

SEC source: 0001543663-26-000017 · wk-form4_1783472909.xml · nonDerivative · entry 2

Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 84,040

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse.

SEC source: 0001543663-26-000017 · wk-form4_1783472909.xml · nonDerivative · entry 1

Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,240

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse.

SEC source: 0001543663-26-000015 · wk-form4_1783032175.xml · nonDerivative · entry 3

Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,840

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $35.255, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001543663-26-000015 · wk-form4_1783032175.xml · nonDerivative · entry 2

Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,370

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.05 to $34.99, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001543663-26-000015 · wk-form4_1783032175.xml · nonDerivative · entry 1

Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,901

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.005 to $34.095, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001543663-26-000013 · wk-form4_1778255465.xml · nonDerivative · entry 2

Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 93,640

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.02 to $32.695, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001543663-26-000013 · wk-form4_1778255465.xml · nonDerivative · entry 1

Cvijic Christine Mikail · CIK 0001543663 · Director · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 98,440

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.31, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001934412-26-000006 · wk-form4_1778171726.xml · derivative · entry 1

Shafer Christina · CIK 0001934412 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2036-05-05

F1 · derivative.exercise_date: This option represents the right to purchase 120,000 shares of the Issuer's common stock, one quarter of which will vest on April 20, 2027 with the remaining three quarters vesting on the 20th of each month in equal monthly installments through April 20, 2030, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.

SEC source: 0001543663-26-000011 · wk-form4_1774905421.xml · nonDerivative · entry 1

Cvijic Christine Mikail · CIK 0001543663 · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,240

F1 · kind: On March 26, 2026, a Restricted Stock Unit ("RSU") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.10 to $21.91, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001606302-26-000005 · wk-form4_1774905414.xml · nonDerivative · entry 1

McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,344,307

F1 · date: On March 26, 2026, a Restricted Stock Unit ("RSU") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.

F2 · shares: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.67to $22.50, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.

SEC source: 0001968554-26-000005 · wk-form4_1774905406.xml · nonDerivative · entry 1

Jordan Julie · CIK 0001968554 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,472

F1 · date: On March 26, 2026, a Restricted Stock Unit ("RSU") held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.68 to $22.19, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Consist of (a) 5,600 restricted stock units, which vest annually in equal installments on March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units which vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

SEC source: 0001994301-26-000004 · wk-form4_1773784904.xml · nonDerivative · entry 3

Cobb Stuart · CIK 0001994301 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,497

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.97 to $22.16, inclsuive. The reporting person undertakes to provide Neurogene Inc. the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

SEC source: 0001994301-26-000004 · wk-form4_1773784904.xml · nonDerivative · entry 2

Cobb Stuart · CIK 0001994301 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,645

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.97 to $21.96, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

SEC source: 0001994301-26-000004 · wk-form4_1773784904.xml · nonDerivative · entry 1

Cobb Stuart · CIK 0001994301 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,303

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.94 to $20.93, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

SEC source: 0001543663-26-000007 · wk-form4_1773784859.xml · nonDerivative · entry 3

Cvijic Christine Mikail · CIK 0001543663 · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,798

F1 · kind: On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.075, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001543663-26-000007 · wk-form4_1773784859.xml · nonDerivative · entry 2

Cvijic Christine Mikail · CIK 0001543663 · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,061

F1 · kind: On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.92 to $21.91, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001543663-26-000007 · wk-form4_1773784859.xml · nonDerivative · entry 1

Cvijic Christine Mikail · CIK 0001543663 · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,456

F1 · kind: On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.92 to $20.87, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001543663-26-000005 · wk-form4_1772575431.xml · nonDerivative · entry 1

Cvijic Christine Mikail · CIK 0001543663 · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,843

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.325. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.direct: Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001706301-26-000002 · wk-form4_1771976443.xml · derivative · entry 1

Noonberg Sarah B. · CIK 0001706301 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,050

Underlying: Common Stock · 12,050 shares

Expires 2036-02-20

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001628280-26-011325 · wk-form4_1771976881.xml · derivative · entry 1

PALEKAR ROHAN · CIK 0001423327 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,050

Underlying: Common Stock · 12,050 shares

Expires 2036-02-20

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001994301-26-000002 · wk-form4_1771976976.xml · nonDerivative · entry 1

Cobb Stuart · CIK 0001994301 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,294

F1 · shares: Consist of 16,500 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

F2 · balance_after: Consist of (a) 13,594 restricted stock units remaining from a grant of 20,391 restricted stock units granted on March 13, 2024, which vests annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 7,200 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

SEC source: 0001543663-26-000002 · wk-form4_1771976938.xml · derivative · entry 2

Cvijic Christine Mikail · CIK 0001543663 · President and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,900

Underlying: Common Stock · 131,900 shares

Expires 2036-02-20

F3 · derivative.exercise_date: This option represents the right to purchase 131,900 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.

SEC source: 0001543663-26-000002 · wk-form4_1771976938.xml · nonDerivative · entry 1

Cvijic Christine Mikail · CIK 0001543663 · President and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,643

F1 · shares: Consist of 22,000 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

F2 · balance_after: Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 24,000 are held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001968554-26-000002 · wk-form4_1771976961.xml · derivative · entry 2

Jordan Julie · CIK 0001968554 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,600

Underlying: Common Stock · 29,600 shares

Expires 2036-02-20

F3 · derivative.exercise_date: This option represents the right to purchase 29,600 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.

SEC source: 0001968554-26-000002 · wk-form4_1771976961.xml · nonDerivative · entry 1

Jordan Julie · CIK 0001968554 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,300

F1 · shares: Consist of 4,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

F2 · balance_after: Consist of (a) 8,400 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

SEC source: 0001606302-26-000002 · wk-form4_1771976903.xml · derivative · entry 2

McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,100

Underlying: Common Stock · 155,100 shares

Expires 2036-02-20

F3 · derivative.exercise_date: This option represents the right to purchase 155,100 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.

SEC source: 0001606302-26-000002 · wk-form4_1771976903.xml · nonDerivative · entry 1

McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,347,659

F1 · shares: Consist of 25,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

F2 · balance_after: Includes (a) 23,900 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 25,900 restricted stock units granted on February 20, 2029, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Due to an administrative error, the amount reported in Column 5 on the Reporting Person's Form 4 filed on March 28, 2025 was understated by the 47,500 shares reported as purchased by the Reporting Person on the Reporting Person's Form 4 filed on November 25, 2024. This Form 4 reflects the correct amount of common stock beneficially owned by the Reporting Person.

SEC source: 0001274826-26-000002 · wk-form4_1771976497.xml · derivative · entry 1

BAFFI ROBERT · CIK 0001274826 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,050

Underlying: Common Stock · 12,050 shares

Expires 2036-02-20

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001832569-26-000002 · wk-form4_1771976424.xml · derivative · entry 1

Freedland Cory S. · CIK 0001832569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,050

Underlying: Common Stock · 12,050 shares

Expires 2036-02-20

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001996804-26-000002 · wk-form4_1771976400.xml · derivative · entry 1

Woods Keith · CIK 0001996804 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,050

Underlying: Common Stock · 12,050 shares

Expires 2036-02-20

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001404644-25-000064 · wk-form4_1749830742.xml · derivative · entry 1

Noonberg Sarah B. · CIK 0001706301 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,050

Underlying: Common Stock · 12,050 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001404644-25-000066 · wk-form4_1749830797.xml · derivative · entry 1

PALEKAR ROHAN · CIK 0001423327 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,050

Underlying: Common Stock · 12,050 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001404644-25-000068 · wk-form4_1749830856.xml · derivative · entry 1

BAFFI ROBERT · CIK 0001274826 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,050

Underlying: Common Stock · 12,050 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001404644-25-000065 · wk-form4_1749830770.xml · derivative · entry 1

Freedland Cory S. · CIK 0001832569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,050

Underlying: Common Stock · 12,050 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001404644-25-000067 · wk-form4_1749830826.xml · derivative · entry 1

Woods Robert Keith · CIK 0001995131 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,050

Underlying: Common Stock · 12,050 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly beginning July 12, 2025 until the option is fully vested on June 12, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001996804-26-000009 · wk-form4a_1781645516.xml · derivative · entry 1

Woods Keith · CIK 0001996804 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,050

Underlying: Common Stock · 12,050 shares

Expires 2035-06-12

F1 · derivative.exercise_date: This option is fully vested.

SEC source: 0001404644-25-000046 · wk-form4_1747341779.xml · nonDerivative · entry 1

Cobb Stuart · CIK 0001994301 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,794

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.78 to $15.75. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001404644-25-000025 · wk-form4_1743211830.xml · derivative · entry 2

Cobb Stuart · CIK 0001994301 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,900

Underlying: Common Stock · 42,900 shares

Expires 2035-03-26

F2 · derivative.exercise_date: This option represents the right to purchase 42,900 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal month installments through the fourth anniversary of the grant date.

SEC source: 0001404644-25-000025 · wk-form4_1743211830.xml · nonDerivative · entry 1

Cobb Stuart · CIK 0001994301 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,591

F1 · shares: Consists of 7,200 restricted stock units, which will vest in three equal annual installments beginning with the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

SEC source: 0001404644-25-000023 · wk-form4_1743211773.xml · derivative · entry 2

Cvijic Christine Mikail · CIK 0001543663 · President and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,000

Underlying: Common Stock · 122,000 shares

Expires 2035-03-26

F3 · derivative.exercise_date: This option represents the right to purchase 122,000 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the date of grant with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.

SEC source: 0001404644-25-000023 · wk-form4_1743211773.xml · nonDerivative · entry 1

Cvijic Christine Mikail · CIK 0001543663 · President and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,643

F1 · shares: Consist of 20,300 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

F2 · ownership.direct: Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001404644-25-000021 · wk-form4_1743211701.xml · derivative · entry 2

Jordan Julie · CIK 0001968554 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,300

Underlying: Common Stock · 50,300 shares

Expires 2035-03-26

F2 · derivative.exercise_date: This option represents the right to purchase 50,300 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.

SEC source: 0001404644-25-000021 · wk-form4_1743211701.xml · nonDerivative · entry 1

Jordan Julie · CIK 0001968554 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,400

F1 · shares: Consist of 8,400 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

SEC source: 0001404644-25-000020 · wk-form4_1743211653.xml · derivative · entry 2

McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,500

Underlying: Common Stock · 143,500 shares

Expires not disclosed

F2 · derivative.expiration_date: This option represents the right to purchase 143,500 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.

SEC source: 0001404644-25-000020 · wk-form4_1743211653.xml · nonDerivative · entry 1

McMinn Rachel · CIK 0001606302 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,274,259

F1 · shares: Consist of 23,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

SEC source: 0001404644-25-000007 · wk-form4_1742246088.xml · nonDerivative · entry 1

Cvijic Christine Mikail · CIK 0001543663 · President and CFO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,343

F1 · kind: On March 12, 2024, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sale reported on this Form 4 relates exclusively to this mandatory sale upon vesting of the RSU.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.38 to $17.21, inclusive. The reporting person undertakes to provide to the Registrant, any security holder of the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3 · ownership.direct: Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic.

SEC source: 0001415889-24-027861 · form4-11272024_091125.xml · nonDerivative · entry 4

Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara BioCapital, L.P.

Disclosed balance after: 1,717,127

F5 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $27.48 to $27.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

SEC source: 0001415889-24-027861 · form4-11272024_091125.xml · nonDerivative · entry 3

Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

AKKARAJU SRINIVAS · CIK 0001253170 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara BioCapital, L.P.

Disclosed balance after: 1,715,127

F4 · price: The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.46 to $26.90 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Securities are held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.